CG Oncology, Inc. Common stock
NASDAQ:CGONBiotechnology
+$1.35 today
- Market cap
- $7.15B
- Beta
- 0.31
- P/E (TTM)
- -28.0
- EPS (TTM)
- -$2.21
Volume 1.79M
Average 1.08M
CGON Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
CG Oncology, Inc. Common stockNASDAQ: CGON
Net Debt · Q3 FY2026 · quarter ended Sep 2026
Net debt remains negative
Q3 FY2026 net debt was -$19.01M, compared with -$37.9M a year earlier.
Context
- Net debt amounted to 1.8% of total assets at the end of Q3 FY2026, down 3.4 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +49.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (25.47M) USD
- Year-over-year change
- +90.1%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (25.47M) | +90.1% |
| FY2024 | 2024-12-31 | (256.83M) | -3449.3% |
| FY2023 | 2023-12-31 | (7.24M) | +90.0% |
| FY2022 | 2022-12-31 | (72.2M) | -87.6% |
| FY2021 | 2021-12-31 | (38.48M) | — |
Net Debt vs competitors
How CGON compares with its peers on the latest reported figures
- CGON's Sep 2026 net debt of -$19.01M is the lowest of the 3 companies compared; the peer median is $455.12M.
- Its year-over-year change of +49.8% is the lowest of 3, against a peer median of +190.6%.
- Net debt amounts to 1.8% of total assets for CGON, versus a peer median of 84.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $824.44M | +71.0% | +8.5% | 135.3% | |
| Mar 2026 | $85.8M | +310.2% | -26.2% | 33.8% | |
| Sep 2026 | -$19.01M | +49.8% | — | 1.8% | |
| Peer median (excluding CGON) | $455.12M | +190.6% | -8.9% | 84.6% | |
Competitors are the stored peer set for CGON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 53.61M | 88.14M | 8.27M | 257.07M | 32.49M |
| Short-term Investments | 0 | 55.34M | 179.41M | 484.93M | 709.67M |
| Net Receivables | 2K | 303K | 92K | 781K | 688K |
| Inventory | 0 | 0 | 0 | 0 | 1.57M |
| Other Current Assets | 4.8M | 3.42M | 6.36M | 11.43M | 15.07M |
| Total Current Assets | 58.41M | 147.21M | 194.12M | 754.21M | 759.48M |
| Property, Plant & Equipment (Net) | 200K | 506K | 491K | 493K | 19.57M |
| Goodwill | 0 | 0 | 0 | 0 | 10.3M |
| Intangible Assets | 0 | 0 | 0 | 0 | 575K |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 85K | 33K | 4.69M | 94K | 1.68M |
| Total Non-current Assets | 285K | 539K | 5.18M | 587K | 32.12M |
| Total Assets | 58.69M | 147.75M | 199.3M | 754.8M | 791.59M |
| Account Payables | 1M | 985K | 3.24M | 6.52M | 5.71M |
| Short-term Debt | 2.94M | 8.97M | 569K | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 286K |
| Other Current Liabilities | 1.13M | 173K | 547K | 436K | 9.02M |
| Total Current Liabilities | 5.98M | 15.43M | 14.25M | 21.37M | 30.84M |
| Long-term Debt | 12.06M | 6.53M | 0 | 0 | 3M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 307K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 351K | 352K | 13K | 0 | 1.74M |
| Total Non-current Liabilities | 12.47M | 7.14M | 257K | 52K | 8.15M |
| Total Liabilities | 18.44M | 22.57M | 14.51M | 21.42M | 38.99M |
| Common Stock | 3K | 0 | 0 | 8K | 8K |
| Retained Earnings | (45.89M) | (81.34M) | (129.94M) | (217.98M) | (378.98M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 40.25M | 125.18M | 184.79M | 733.38M | 752.6M |
| Total Debt | 15.13M | 15.94M | 1.03M | 238K | 7.02M |
| Net Debt | (38.48M) | (72.2M) | (7.24M) | (256.83M) | (25.47M) |
CG Oncology, Inc. Common stock
NASDAQ:CGON
Intrinsic Alpha fair value
Locked
Current Price
$80.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.